Home
  >  
Section 1
  >  
Chapter 775

The fate of silvex following oral administration to humans

Sauerhoff, M.W.; Chenoweth, M.B.; Gordon, H.L.; Braun, W.H.; Blau, G.E.; Gehring, P.J.

Toxicology and Applied Pharmacology 41(1): 162-163

1977

ISSN/ISBN: 0041-008X
Accession: 000774799
Download citation:  
Text
  |  
BibTeX
  |  
RIS
No adverse effect on humans was observed following oral administration of fenoprop at 1 mg/kg. Apparent first-order kinetics described the biphasic clearance of fenoprop from plasma and its excretion in urine. Peak plasma concns. of fenoprop occurred within 2-4 h. Within 24 h of administration 65% of the dose had been excreted in the urine and relatively small amounts (up to 3.2%) were eliminated in the faeces. Recovery of fenoprop and its conjugates in urine and faeces up to 168 h ranged from 66.6 to 95.1%. From summary.

PDF emailed within 1 workday: $29.90




Related References

Sauerhoff, M.W.; Chenoweth, M.B.; Karbowski, R.,.; Braun, W.H.; Ramsey, J.C.; Gehring, P.J.; Blau, G.E. 1977: Fate of silvex following oral administration to humans Journal of Toxicology and Environmental Health 3(5-6): 941-952
Beer, C.T.; Gallagher, T.F. 1955: Excretion of estrogen metabolites by humans. II. The fate of large doses of estradiol-17B after intramuscular and oral administration Journal of Biological Chemistry 214(1): 351-364
Beer, C.T.; Gallagher, T.F. 1955: Excretion of estrogen metabolites by humans. II. the fate of large doses of estradiol-17beta after intramuscular and oral administration Journal of Biological Chemistry 214(1): 351-364
Cawello, W.; Boekens, H.; Bonn, R. 2012: Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration European Journal of Drug Metabolism and Pharmacokinetics 37(4): 241-248
Tanaka, N.; Yamasaki, Y.; Yamada, H.; Suzuki, H.; Sano, S.; Hirota, A.; Nagoshi, H.; Kinoshita, K. 1981: Fate of cobalamins in humans following oral and intra muscular administration of cyano cobalamin hydroxo cobalamin adenosyl cobalamin and methyl cobalamin Vitamins 55(3): 155-162
S.J.hn, L.E.; Wagner, D.G.; Lisk, D.J. 1964: Fate of Atrazine, Kuron, Silvex, and 2,4,5-T in the dairy cow J Dairy Sci 47(11): 1267-1270
Bailey, G.W.; Thruston, A.D.; Pope, J.D.; Cochrane, D.R. 1970: The Degradation Kinetics of an Ester of Silvex and the Persistence of Silvex in Water and Sediment Weed Science 18(3): 413-419
Ichikawa, M.; Haruki, S.; Esumi, Y.; Takaichi, M.; Seki, H.; Miyake, T.; Hagiya, H.; Shiina, M. 1992: Metabolic fate of Bevantolol hydrochloride : metabolic fate after repeated oral administration, and transfer into fetus and milk rats Yakuri to Chiryo 20(5): 229-241
Shindo, H.; Komai, T.; Nakajima, E. 1972: Metabolic fate and mechanism of action of chloroethylthiamine. II. Movement and fate of chloroethylthiamine along intestinal lumen after oral administration to chick Journal of Vitaminology 18(1): 48-54
Berger, E.G.; Moehr, P. 1976: Oral versus intravenous administration of butylbiguanide: effect on oral glucose tolerance in normal humans European Journal of Clinical Investigation 6(3): 221-228
Moldoveanu, Z.; Oliver, F.; Mestecky, J.; Elson, C.O. 2004: Oral tolerance in humans: failure to suppress an existing immune response by oral antigen administration Annals of the new York Academy of Sciences 1029: 299-309
Sauerhoff, M.W.; Braun, W.H.; Blau, G.E.; Gehring, P.J. 1977: The fate of 2 4 d following oral administration to man Toxicology 8(1): 3-12
Gehring, P.J.; Kramer, C.G.; Schwetz, B.A.; Rose, J.Q.; Rowe, V.K.; Zimmer, J.S. 1973: The fate of 2 4 5 t following oral administration to man Toxicology and Applied Pharmacology 25(3): 441
Binnert, C.; Pachiaudi, C.; Beylot, M.; Croset, M.; Cohen, R.; Riou, J.P.; Laville, M. 1996: Metabolic fate of an oral long-chain triglyceride load in humans American Journal of Physiology 270(3 Part 1): E445-E450
Ashbel, S.I.; Khil, R.G.; Sokolova, V.G.; Pertsovich, I.K. 1971: Fate of sulfamonomethoxine following per oral administration Kazanskii Meditsinskii Zhurnal 4: 40-41
Taira, K.; Yasuda, Y.; Shindo, T.; Mitani, N.; Akazawa, A. 1980: The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 100(3): 272-279
Shindo, H.; Komai, T.; Nakajima, E. 1971: Metabolic fate and mechanism of action of chloroethyl thiamine part 2 movement and fate of chloroethyl thiamine along intestinal lumen after oral administration to chick Journal of Vitaminology 18(1): 48-54
Sauerhoff, M.W.; Braun, W.H.; LeBeau, J.E. 1977: Dose-dependent pharmacokinetic profile of silvex following intravenous administration in rats Journal of Toxicology and Environmental Health 2(3): 605-618
Actor, P.; Pitkin, D.H.; Lucyszyn, G.; Weisbach, J.A.; Bran, J.L. 1976: Cefatrizine (SK&F 60771), a new oral cephalosporin: serum levels and urinary recovery in humans after oral or intramuscular administration--comparative study with cephalexin and cefazolin Antimicrobial Agents and ChemoTherapy 9(5): 800-803
Actor, P.; Pitkin, D.H.; Lucyszyn, G.; Weisbach, J.A.; Bran, J.L. 1976: Cefatrizine (Sk&F 60771), a New Oral Cephalosporin: Serum Levels and Urinary Recovery in Humans After Oral or Intramuscular Administration - Comparative Study with Cephalexin and Cefazolin Antimicrobial Agents and Chemotherapy 9(5): 800-803